Details of the Drug Combinations

General Information of This Drug (ID: DMY6WUV)

Drug Name

GDC-0077 DMY6WUV

Synonyms

RG6114; SGEUNORSOZVTOL-CABZTGNLSA-N; UNII-L4C1UY2NYH; L4C1UY2NYH; 2060571-02-8; GDC0077; GTPL9636; SCHEMBL18360780; EX-A2685; ZINC669678973; Ro7113755; CS-6459; HY-101562; Propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)-, (2S)-; (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide; (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxa

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
Breast cancer	2C60-2C65	Phase 1	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

9 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Atovaquone + GDC-0077	DCLMT5N	Atovaquone	Hepatoblastoma (Cell Line: HB3)	[3]
Bafilomycin A1 + GDC-0077	DCVLGBA	Bafilomycin A1	DD2 (Cell Line: DD2)	[3]
GDC-0077 + Panobinostat	DCRRN4U	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
GDC-0077 + Quinine	DCC8J31	Quinine	DD2 (Cell Line: DD2)	[3]
GDC-0077 + Pyronaridine	DC4LXZ3	Pyronaridine	DD2 (Cell Line: DD2)	[3]
GDC-0077 + Ruxolitinib	DCV35SF	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]
LY3023414 + GDC-0077	DCHHHDH	LY3023414	DD2 (Cell Line: DD2)	[3]
Midostaurin + GDC-0077	DC98PXJ	Midostaurin	Hepatoblastoma (Cell Line: HB3)	[4]
Panobinostat + GDC-0077	DCTGA9K	Panobinostat	Hepatoblastoma (Cell Line: HB3)	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 DrugCom(s)

References

1	ClinicalTrials.gov (NCT04632992) A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.